Caribou Biosciences, Inc., a Berkeley, California-based developer of CRISPR-Cas technologies for genome engineering, completed a $30m Series B funding round.
Backers included new investors Anterra Capital, Heritage Group, Maverick Capital Ventures, and Pontifax AgTech as well as existing investors F-Prime Capital Partners, Novartis, Mission Bay Capital, and 5 Prime Ventures.In conjunction with the funding, Philip Austin, Founding Partner at Anterra Capital, joined Caribou’s Board of Directors.
The company intends to use the funds to continue to expand the CRISPR gene editing technology platform and accelerate efforts in additional application areas in agriculture, therapeutics, biological research, and industrial biotechnology.
Led by Rachel Haurwitz, Ph.D., President and Chief Executive Officer and co-founder, Caribou is a developer of cellular engineering and analysis solutions based on CRISPR technologies, which provide enhanced capabilities to therapeutic development, agricultural biotechnology, industrial biotechnology, and basic and applied biological research.
The company is founded by pioneers of CRISPR-Cas biology based on research carried out in the Doudna Laboratory at the University of California, Berkeley.